Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The bovine Ack is called Ack
2023-12-14

The bovine Ack is called Ack2 (bAck2) and has been suggested to act as a clathrin-assembly protein regulated by the small GTPase Cdc42 [17]. bAck2 lacks some of the C-terminal parts when compared to hAck1 and mAck1. Both Ack1 and Ack2 have been demonstrated to interact with sorting nexin 9 (SNX9 or
-
Compound mg was purified as an amorphous colourless powder M
2023-12-14

Compound 3 (29 mg) was purified as an amorphous, colourless powder. Molecular formula C20H28O4 was established by HRESIMS (Fig. S11) and corroborated with 1H and 13C NMR spectroscopic data (Table 1). IR spectrum showed bands for hydroxyl (3433 cm−1) and carbonyl (1686 cm−1) groups. 13C NMR spectrum
-
Aurora B is also known as chromosomal passenger protein
2023-12-13

Aurora-B is also known as chromosomal passenger protein and localizes at the chromosome arms and at centromeres during prophase. As cell cycle continues, Aurora-B moves towards the inner centromere region followed by the central spindle and cortex during amide pka and finally accumulates in the midb
-
AP activation is known to upregulate downstream target genes
2023-12-13

AP-1 activation is known to upregulate downstream target genes including GSK2334470 D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in
-
AZD-9291 mesylate synthesis br Concluding remarks and future
2023-12-13

Concluding remarks and future perspectives While the rational engineering of protein-based switches has yet to be fully developed, emerging empirical rules facilitate the construction of tailor-engineered AZD-9291 mesylate synthesis with custom input and output parameters. Both in the context of
-
br Antifungal resistance what is in
2023-12-13

Antifungal resistance, what is in a name? Antifungal resistance is an emerging and hot topic in the field of medical mycology. Microbiological resistance is identified by determining minimal inhibitory concentrations (MICs) in vitro for a given antifungal and interpreting this value according to
-
Echinocandin resistance is systematically associated with po
2023-12-13

Echinocandin resistance is systematically associated with point mutations in either FSK1 or FSK2 genes [7], [104]. These mutations are located in two different not spot regions of these genes named HS1 and HS2. Hot spot mutations have been reported in C. albicans, C. glabrata, C. tropicalis, C. krus
-
As an internal control this study
2023-12-13

As an internal control, this study validated many of the known associations between GATA3 and predictive markers. GATA3 was shown to be associated with ER and PR, which are both well-known correlations. GATA3 was also negatively correlated with nuclear grade, which is consistent with our knowledge o
-
Intracellular Signaling Cascades From ligand sensitization
2023-12-13

Intracellular Signaling Cascades. From ligand sensitization to translation of genes, all cellular processes are dependent on the intracellular levels and activity of partners involved in the signaling pathway. These signaling events lead to critical post-translational modifications including phospho
-
br Author contributions br Financial disclosures br Acknowle
2023-12-13

Author contributions Financial disclosures Acknowledgements We thank Ms. Eva So for the editorial assistance. This work was supported by grants from the National Natural Science Foundation of China (No. 81622015, 81571042 and 81501143) and the National Basic Research Program of China (No. 2
-
br Concluding Remarks and Future Perspectives While postmort
2023-12-13

Concluding Remarks and Future Perspectives While postmortem human GSK2118436 material is relatively sparse and has inherent limitations as discussed above, additional investigations could benefit from analysis of in vitro cellular models to corroborate findings in patient material. Generation of
-
br Introduction There are greater
2023-12-13

Introduction There are greater than five million Americans living with Alzheimer's dementia and more than 35 million people worldwide [1], and without a way to stop or slow the progression, there will be nearly a tripling of individuals affected by 2050 (13.8 million) [1]. The urgency to develop
-
In this study we designed and
2023-12-13

In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci
-
Notably AR and AR signaling can also occur via mechanisms
2023-12-13

Notably, β2AR and β3AR signaling can also occur via mechanisms independent from G protein [13]. Additionally, the response to GPCR stimulus can be modified by various parameters, including chronic stimulation, cell hypoxia, acidosis, and aging [14], [15], [16]. GRKs have a significant role in the r
-
We also demonstrate that PACAP treatment dose dependently
2023-12-13

We also demonstrate that PACAP treatment dose-dependently disrupts performance in the 5CSRTT, suggestive of attentional deficits, another core feature of mood and anxiety disorders. Treatment with PACAP (.5–1.0 µg) decreased the percentage of correct responses, increased the percentage of trials in
15282 records 240/1019 page Previous Next First page 上5页 236237238239240 下5页 Last page